Άρθρο του Ahmet Gençtürk για τη θεραπεία του καρκίνου - Δήλωση του τ. Πρύτανη ΕΚΠΑ, Καθηγητή Ογκολογίας-Αιματολογίας και Διευθυντή της Θεραπευτικής Κλινικής Θάνου Δημόπουλου:
" Meletios-Thanos Dimopoulos, a senior oncologist at Athens University’s Medical School, asserted that the vaccine fundamentally differs from other kinds of immunotherapy, which involves antibodies enhancing the immune system's ability to eradicate cancer.
“While their efficacy is limited by the inherent immunosuppressive and immune-resistance mechanisms of cancer, the vaccines attempt to bypass these barriers by exposing our immune system to tumor-specific antigens and selectively induce immune response against cancer,” he explained.
“Current technology has enabled mRNA-based vaccines to recognize most potent tumor-specific antigens, antigens specific for each patient’s cancer, as well as to improve induced immune responses,” said Dimopoulos, who served as Greece's caretaker minister of health in 2015.
On the range of cancer types that the vaccines will work against, he said those currently under clinical development have shown efficacy on various forms of the disease.
“Up to now, early phase clinical trials have shown potent immune responses with mRNA vaccines in pancreatic, colorectal, lung, bladder, head, and neck cancer, and melanoma,” he said, adding:
“Further accumulation of clinical data regarding the efficacy of personalized vaccines will most possibly enable their use in several types of cancer in the near future.”
Important to note, he said, is that apart from preventive vaccines against cervical cancer, vaccines currently under development have been designed for use in patients already diagnosed with cancer.
“Clinical data, though, support their use in early-stage carcinomas that have been completely resected surgically. In such cases, therapeutic vaccines either as monotherapy or in combination with other immunotherapeutic approaches seem very potent in preventing cancer recurrence,” Dimopoulos noted.
The vaccines can enter clinical practice as soon as five years from now if trials yield positive results, he said, though for mass use, a period of 10 years is more likely.
On affordability, Dimopoulos said, “Recent experience of vaccines against COVID-19 has proven that mRNA vaccines may be produced in a relatively low cost and a timely manner."